Science
Qymune’s Q²TCE platform introduces a first-in-class, non-CD3 approach to T cell engagement that delivers potent cytotoxicity with markedly reduced cytokine release. Tunable antibody affinities enable application across oncology and autoimmune diseases, expanding patient eligibility and combination potential beyond conventional T cell engagers.
How Q2TCE works differently
T cell engagers are incredibly potent at killing cancer cells, but current CD3-based approaches cause severe cytokine release syndrome. For autoimmune diseases requiring chronic treatment, this toxicity profile is a dealbreaker.
CD3 Engager
vs
Q²TCE
Potency
Achieves deeper tissue depletion than standard antibodies, eliminating hidden reservoirs.
Accessibility
Ready-to-use / Off-the-shelf. Solves the manufacturing delays and high costs of CAR-T.
Platform
Proprietary first-in-class platform
Safety
Optimized toxicity profile. Powerful efficacy without the risks.
Cancer cell
T cell
OUR PLATFORM
Qymune is building a new generation of
T cell–based immunotherapies designed
to overcome the fundamental limitations of current T cell engager (TCE) approaches.
Our platforms are engineered to deliver durable efficacy, precise immune control, and best-in-class safety, enabling applications across oncology and immune-mediated diseases.
Q2TCE — Quiet T Cell Engager Platform
Safety by Design
T Cell Boosting Technology
Enabling Druable Therapeutic Effect
Antibody-Masking Technology
Precision Targeting Through Controlled Activation
Together, these platforms form the foundation of Qymune’s next-generation T cell engager strategy—designed to deliver powerful, durable efficacy with uncompromising patient safety.
